CAC
ORKA

Cowen and Company’s Oruka Therapeutics ORKA Stock Holding History

Cowen and Company’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58,332
Closed -$1.43M – 398
2024
Q3 		$1.43M Sell
58,332
-1
-0% -$35 0.05% 135
2024
Q2 		$2.68M Buy
+58,333
New +$2.33M 0.07% 99

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cowen and Company's ORKA Position: Q4 2024 in Review

Cowen and Company sold out of Oruka Therapeutics (ORKA) in Q4 2024, closing a stake of 58,332 shares — an estimated $1.43M sold.

Cowen and Company first reported a position in ORKA in Q2 2024 and held it in 2 quarters. The position peaked at $2.68M in Q2 2024. 66 funds tracked by Wall St. Rank hold ORKA as of Q4 2024.

  • Cowen and Company reported no remaining Oruka Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 58,332 Oruka Therapeutics shares in Q4 2024, an estimated $1.43M.
  • Cowen and Company first reported a position in Oruka Therapeutics in Q2 2024 and held it in 2 quarters.
  • Cowen and Company's Oruka Therapeutics position peaked at $2.68M in Q2 2024.
  • 66 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.